BioCardia CEO buys 500 shares in open-market trade

BioCardia, Inc. director and President & CEO Peter Altman purchased 500 shares of Common Stock on July 17, 2026 at $0.83 per share in an open-market transaction.

Accepted by SEC EDGAR 07/20/2026 - 04:16 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioCardia, Inc. director and President & CEO Peter Altman purchased 500 shares of Common Stock on July 17, 2026 at $0.83 per share in an open-market transaction. After this trade, he directly owns 368,885 shares of BioCardia common stock.

The filing’s Rule 10b5-1 trading-plan checkbox was not selected.

Insider Trade Summary

Net Buyer: 500 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 500 shs ($415.00)

Type	Security	Shares	Price	Value
Purchase	Common Stock	500	$0.83	$415.00

Holdings After Transaction: Common Stock — 368,885 shares (Direct)

Key Figures

Shares purchased: 500 shares Purchase price: $0.83 per share Holdings after transaction: 368,885 shares +2 more

5 metrics

Shares purchased 500 shares Common Stock bought by Peter Altman on July 17, 2026

Purchase price $0.83 per share Price for the 500-share Common Stock purchase

Holdings after transaction 368,885 shares Peter Altman’s direct BioCardia Common Stock position after the trade

Transaction code P Indicates a purchase in open market or private transaction

Net buy shares 500 shares Net effect across all reported transactions in this Form 4

Key Terms

non-derivative, transaction code, direct or indirect

3 terms

non-derivative regulatory

"The transaction_type is listed as "non-derivative" for the Common Stock trade."

transaction code regulatory

"The Form 4 uses transaction code "P" for the purchase entry."

direct or indirect regulatory

"The field direct_or_indirect is marked "D", indicating direct ownership."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report for Peter Altman?

Peter Altman, BioCardia’s President & CEO, purchased 500 common shares on July 17, 2026 at $0.83 per share. Following this open-market trade, his direct holdings increased to 368,885 BioCardia shares.

How many BioCardia (BCDA) shares does Peter Altman hold after this Form 4?

After the reported transaction, Peter Altman directly holds 368,885 shares of BioCardia common stock. This reflects an open-market purchase of 500 shares at $0.83 per share on July 17, 2026, as disclosed in the Form 4.

What price did Peter Altman pay for his latest BioCardia (BCDA) share purchase?

Peter Altman paid $0.83 per share for his recent purchase of 500 BioCardia common shares on July 17, 2026. The transaction was classified as a purchase in the open market or private transaction.

Was the BioCardia (BCDA) insider trade under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 trading-plan checkbox was not selected for this transaction. The July 17, 2026 purchase of 500 shares at $0.83 per share is therefore not identified as executed under a 10b5-1 plan.

What type of security did Peter Altman acquire in the latest BioCardia (BCDA) filing?

Peter Altman acquired Common Stock of BioCardia in a non-derivative transaction. He bought 500 shares at $0.83 per share on July 17, 2026, bringing his direct holdings to 368,885 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2026		P		500	A	$0.83	368,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David McClung, by power of attorney	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)